DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1956)

Prostate Cancer | Landscape & Forecast | Disease Landscape & Forecast

Prostate Cancer | Landscape & Forecast | Disease Landscape & Forecast

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Market Outlook

Prostate cancer is the most common cancer among men in developed countries. Hormonal agents are the main treatment for prostate cancer and are routinely used throughout the course of the disease. Zytiga (Johnson & Johnson/Janssen Biotech/Janssen-Cilag/AstraZeneca’s abiraterone) and Xtandi (Pfizer/Astellas Pharma’s enzalutamide) are cornerstone treatments of metastatic castrate-resistant prostate cancer (mCRPC) and several clinical trials are evaluating their role in earlier stages of the disease. The late-phase pipeline for mCRPC has also become more dynamic with four PARP inhibitors: AstraZeneca’s Lynparza (olaparib), Clovis Oncology’s Rubraca (rucaparib), Tesaro/Janssen Biotech’s Zejula (niraparib), and Pfizer’s Talzenna (talazoparib); two immune checkpoint inhibitors, Roche/Genentech/Chugai’s Tecentriq (atezolizumab) and Merck Sharp & Dohme’s Keytruda (pembrolizumab); a kinase inhibitor, Array BioPharma/Roche/Genentech /Chugai’s ipatasertib; and a radioligand therapy, Endocyte’s 177Lu-PSMA-617, entering Phase III development.

Questions Answered

  • What factors are driving and constraining market growth? Which new classes of agents will emerge over the forecast period, and what impact will they have on the overall market?
  • How is prostate cancer currently managed, and how will treatment practices change?
  • What is the clinical and commercial potential of late-phase pipeline products, and what will be their likely positioning in the market? How will new market entrants fare through 2027?
  • What are the actionable remaining unmet needs affecting the management of prostate cancer? What are the key drug development and therapeutic opportunities?

Product Description

Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Markets covered:United States, France, Germany, Italy, Spain, United Kingdom, and Japan.

Primary research: More than 20 country-specific interviews with thought-leading medical oncologists, supported by survey data collected for this and other DRG research.

Key companies: Johnson & Johnson, Janssen Biotech, Janssen-Cilag, AstraZeneca, Pfizer, Astellas Pharma, Sanofi, Roche, Tesaro, Clovis Oncology, Endocyte, Merck Sharp & Dohme.

Key drugs: Xtandi (enzalutamide), Zytiga (abiraterone), Erleada (apalutamide), Xofigo (radium-223), Jevtana (cabazitaxel), docetaxel, Yonsa (abiraterone acetate), Lynparza (olaparib), Rubraca (rucaparib), Talzenna (talazoparib), Zejula (niraparib), Tecentriq (atezolizumab), Keytruda (pembrolizumab), 177Lu-PSMA-617.

Table of contents

  • Disease Landscape & Forecast
    • Key Updates
      • March 2019
      • December 2018
      • October 2018
      • August 2018
      • April 2018
    • Market Outlook
      • Key Findings
        • Market Overview
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Prostate Cancer?
        • What Factors Are Constraining the Market for Prostate Cancer?
      • Segment-Specific Trends
        • Hormone-Sensitive Prostate Cancer
        • Non-Metastatic Castrate-Resistant Prostate Cancer
        • First-Line Metastatic Castrate-Resistant Prostate Cancer
        • Second- and Subsequent-Line Metastatic Castrate-Resistant Prostate Cancer
    • Forecast
      • Market Forecast Assumptions
      • Market Forecast Dashboard
    • Etiology and Pathophysiology
      • Key Findings
        • Disease Overview
      • Disease Pathophysiology
        • Biology and Metastatic Spread of Prostate Cancer
        • Prostate-Specific Antigen
        • Staging Classification and Grading Systems for Prostate Cancer
        • Development of Castrate-Resistant Prostate Cancer
      • Key Pathways and Drug Targets
        • Androgen Receptor Signaling Pathway
        • Splice Variants of the Androgen Receptor
        • Emerging Drug Targets in Prostate Cancer
    • Epidemiology
      • Introduction
        • Key Findings
      • Epidemiology Populations
        • Newly Diagnosed Incident Cases
        • TNM Stage Distribution and NCCN Risk Category
        • Recurrent Incident Cases
        • Drug-Treatable Populations
        • Drug-Treated Populations
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • Hormonal Agents
        • Immunotherapies
        • Bone-Metastases-Targeted Agents
        • Cytotoxic Agents
      • Medical Practice
        • Newly Diagnosed, Low- and Intermediate-Risk Hormone-Sensitive Prostate Cancer
        • Newly Diagnosed, High- and Very-High-Risk Hormone-Sensitive Prostate Cancer
        • Newly Diagnosed, Metastatic Hormone-Sensitive Prostate Cancer
        • Biochemically Recurrent Prostate Cancer
        • Non-Metastatic Castrate-Resistant Prostate Cancer
        • First-Line Metastatic Castrate-Resistant Prostate Cancer
        • Second- and Subsequent-Line Metastatic Castrate-Resistant Prostate Cancer
        • Treatment Guidelines
        • Region-Specific Treatment Practices
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in Prostate Cancer
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • Notable Developments Among Key Emerging Therapies for Prostate Cancer
        • Hormonal Agents
        • Immunotherapies
        • PARP Inhibitors
        • Kinase Inhibitors
        • Radioligand Therapy
      • Early-Phase Pipeline Analysis
        • Notable Developments in the Early-Phase Pipeline for Prostate Cancer
    • Access and Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
      • Looking for More?
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug- and Regimen-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • General Statements About Pricing
        • Dosing, Cycles of Therapy, and Compliance
        • Generic Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Prostate Cancer Bibliography

Already a Client? Log in to access this report.

  • Pub Date: March 2019
  • Author(s): Carolina do Pazo, M.Sc; Narendra Parihar
  • Carolina do Pazo, is a Business Insights Analyst in the oncology division at Decision Resources Group. Prior to joining DRG, she completed a MSc in Biotechnology, Bioprocessing and Business Management with distinction at the University of Warwick, as a Chevening scholar. She also earned her first-class BSc and BEng in Biotechnology from the Universidad ORT. Ms. do Pazo has worked as a Research Scientist at the Institut Pasteur de Montevideo, analysing the ageing process of yeast cells, and has been part of a project between Indiana University and Universidad ORT that analysed the production of nanohybrids for drug delivery systems applications.

  • Narendra is an associate epidemiologist within the epidemiology team at Decision Resources Group. Narendra specializes in developing epidemiological forecasts for multiple indications within the DRG syndicated portfolio. His qualifications include an MPH with specialization in Health Policy, Economics and Finance from the Tata Institute of Social Sciences, Mumbai, and a Bachelor’s degree in Dentistry from the Rajasthan University of Health Sciences.

Purchase Report

Recent reports:
You may also be interested in: